Dynavax Technologies Corp (DVAX)
11.01
-0.64
(-5.49%)
USD |
NASDAQ |
May 09, 16:00
11.00
0.00 (0.00%)
After-Hours: 20:00
Dynavax Technologies Enterprise Value: 918.46M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 09, 2024 | 918.46M |
May 08, 2024 | 1.002B |
May 07, 2024 | 1.016B |
May 06, 2024 | 1.001B |
May 03, 2024 | 1.014B |
May 02, 2024 | 1.011B |
May 01, 2024 | 1.006B |
April 30, 2024 | 965.49M |
April 29, 2024 | 961.57M |
April 26, 2024 | 944.59M |
April 25, 2024 | 939.36M |
April 24, 2024 | 972.02M |
April 23, 2024 | 1.016B |
April 22, 2024 | 1.027B |
April 19, 2024 | 1.022B |
April 18, 2024 | 961.57M |
April 17, 2024 | 973.32M |
April 16, 2024 | 981.16M |
April 15, 2024 | 1.007B |
April 12, 2024 | 1.027B |
April 11, 2024 | 1.049B |
April 10, 2024 | 1.041B |
April 09, 2024 | 1.050B |
April 08, 2024 | 1.054B |
April 05, 2024 | 1.054B |
Date | Value |
---|---|
April 04, 2024 | 1.058B |
April 03, 2024 | 1.073B |
April 02, 2024 | 1.088B |
April 01, 2024 | 1.124B |
March 28, 2024 | 1.101B |
March 27, 2024 | 1.101B |
March 26, 2024 | 1.096B |
March 25, 2024 | 1.113B |
March 22, 2024 | 1.086B |
March 21, 2024 | 1.069B |
March 20, 2024 | 1.061B |
March 19, 2024 | 1.050B |
March 18, 2024 | 1.009B |
March 15, 2024 | 1.054B |
March 14, 2024 | 1.050B |
March 13, 2024 | 1.070B |
March 12, 2024 | 1.131B |
March 11, 2024 | 1.174B |
March 08, 2024 | 1.197B |
March 07, 2024 | 1.155B |
March 06, 2024 | 1.143B |
March 05, 2024 | 1.122B |
March 04, 2024 | 1.144B |
March 01, 2024 | 1.147B |
February 29, 2024 | 1.135B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
211.41M
Minimum
Jul 30 2019
2.318B
Maximum
Nov 03 2021
963.36M
Average
1.011B
Median
Dec 23 2022
Enterprise Value Benchmarks
Supernus Pharmaceuticals Inc | 1.387B |
Esperion Therapeutics Inc | 576.14M |
Deciphera Pharmaceuticals Inc | 1.744B |
Ligand Pharmaceuticals Inc | 1.236B |
Pacira BioSciences Inc | 1.584B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 0.219M |
Revenue (Quarterly) | 55.60M |
Total Expenses (Quarterly) | 64.09M |
Gross Profit Margin (Quarterly) | 84.37% |
Profit Margin (Quarterly) | 0.39% |
Earnings Yield | -0.54% |
Normalized Earnings Yield | 0.0992 |